Dr. Klempner completed his residency in internal medicine at Brigham and Women’s Hospital/Harvard Medical School, followed by a combined hematology-oncology fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School. While at Harvard Dr. Klempner studied the mechanisms of resistance to targeted therapies in tumor cells in the lab of Dr. Lewis Cantley, PhD. Dr. Klempner is board certified in medical oncology, hematology, and internal medicine, and belongs to several oncology research societies including the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), the American Association for Cancer Research (AACR). His work has been published in multiple journals including Journal of Clinical Oncology (JCO), Cancer Discovery, Lancet Oncology, JAMA Oncology, Annals of Oncology and others. He is an active member of the ASCO TAPUR trial molecular tumor board and serves on the editorial board of JCO Precision oncology.
As a member of the gastrointestinal cancer group at MGH Dr. Klempner works in a multidisciplinary team to optimize and individualize treatment using molecular characterization across all stages of GI cancers. He conducts clinical trials and translational research with new targeted agents and immune therapies, and is active in the gastroesophageal cancer community where he serves on the advisory board of Debbie's Dream Foundation and Hope for Stomach Cancer. He has received several awards for his care of patients with GI cancers. Originally from Wayland, MA he is an avid Boston sports fan.
Departments, Centers, & Programs:
Clinical Interests:
Treats:
Languages:
Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-724-4000
Phone: 617-643-4976
Fax: 617-726-0452
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Klempner's research is focused on identifying molecular subgroups in gastric and esophageal cancers and translating this information to new treatment approaches for these difficult cancers. He has interests in circulating tumor DNA, cancer biomarkers, and peritoneal disease and ascites in GI cancers.
FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist. 2019 Jun 27;. doi: 10.1634/theoncologist.2019-0121.
Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.Oncologist. 2019 Apr;24(4):475-482.
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clin Cancer Res. 2018 Apr 15;24(8):1881-1890.
